* EyeArt has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
Capture color retinal fundus
images of the patient's eyes
Submit images to the
cloud for analysis
Download DR screening results and
export PDF report.
Easy to use. Detailed screening report.
Any physician can quickly and accurately detect more than mild and vision-threatening diabetic retinopathy in patients during a diabetic patient’s regular exam with a report that is generated in less than 60 seconds after submission of patient images.
Immediate, On-site Diabetic Retinopathy Screening
The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible. Any physician can quickly and accurately detect referable diabetic retinopathy patients within minutes during a diabetic patient’s regular exam.
High Sensitivity & Specificity ⇒ Better Safety and Better Outcomes
Demonstrates over 91% referable DR screening sensitivity and specificity in a retrospective study of over 100,000 consecutive patient visits, with over 98.5% sensitivity in identifying patients with potentially treatable sight threatening DR.
High Sensitivity = Safety | High Specificity = Effectiveness
Can help ensure patients with silently progressing DR are identified in time for referral to an eyecare specialist while reducing unnecessary referrals. Can help focus on those patients with greatest need for care.
Unparalleled, Real World Clinical Validation
EyeArt is the most extensively validated AI technology in the world. It has been tested in a clinical validation study on over 100,000 patient visits, one of the largest data sets used to test any available DR screening technology, in demanding, real-world clinical environments using images captured in everyday practice. It has also been independently validated by UK NHS in a study with over 20,000 patients.
Truly automated, including image quality feedback
Fully automated DR screening, including imaging, grading for DR in accordance with internationally recognized standards and reporting, in a single office visit. No specialist needed for DR screening. EyeArt also flags poor quality images or images not showing the required retinal fields (protocol deviations) automatically.
Flexible, Robust, Secure, Cloud-based Design
The technology is designed to work effectively with image quality commonly encountered in diabetes patients and with imaging protocols/cameras typically used in screening setups. EyeArt is HIPAA compliant and keeps all data secure and private.
Easy-to-read reports in 60 seconds
The EyeArt system autonomously analyzes patient's retinal images to robustly detect signs of disease and returns an easy-to-read report in under 60 seconds. The report provides eye level and patient level diabetic retinopathy outputs and also indicates presence or absence of referable DR or vision threatening DR.
Technology behind EyeArt®
* Products were supported by Award numbers R44EB013585, R42TR000377, R44TR000377, R43EY024848, R43EY025984, SB1EY027241, and R43EY028081 from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessarily represent the official views of NIH.
** The devices are covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.
EyeArt for DR detection has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
EyeMark™, EyeReadUWF™, and Eyenuk products for AMD and Glaucoma have not yet been cleared for sales in any region.